Wave Life Sciences (WVE) Cash & Equivalents (2014 - 2026)

Wave Life Sciences' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $544.6 million for Q1 2026.

• Quarterly Cash & Equivalents rose 124.02% year-over-year to $544.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $544.6 million (up 124.02% YoY) and the FY2025 annual result came in at $602.1 million, up 99.31% from the prior year.
• Cash & Equivalents was $544.6 million for Q1 2026 at Wave Life Sciences, down from $602.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $602.1 million in Q4 2025 and bottomed at $88.5 million in Q4 2022.
• A 5-year average of $231.4 million and a median of $196.2 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 41.22% — and 2023, when it soared 126.39%.
• Wave Life Sciences' Cash & Equivalents stood at $88.5 million in 2022, then jumped by 126.39% to $200.4 million in 2023, then surged by 50.77% to $302.1 million in 2024, then soared by 99.31% to $602.1 million in 2025, then retreated by 9.55% to $544.6 million in 2026.
• Business Quant data shows WVE's Cash & Equivalents at $544.6 million in Q1 2026, $602.1 million in Q4 2025, and $196.2 million in Q3 2025.